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S U M M A R Y
Background: Reactivation of cytomegalovirus (CMV) and human herpesvirus 6 (HHV-6), as well as the
recurrence of hepatitis C virus (HCV), occurs in the post liver transplantation period. However, their
correlations remain questionable. The objectives of this study were to analyze the presence of CMV DNA
and HHV-6 DNA in pre-transplant and post-transplant liver graft biopsies and to determine any
correlations with CMV disease and HCV recurrence.
Methods: Forty-one liver transplant recipients were followed up in the post-transplant period. The
presence of CMV DNA and HHV-6 DNA was detected by nested PCR.
Results: Four patients (4/41, 9.8%) were positive for CMV DNA in pre-transplant biopsies and three of
them remained positive after transplantation; 11 patients became positive in the post-transplant
biopsies (p = 0.06). Fifteen (15/41, 36.6%) patients were positive for HHV-6 DNA in pre-transplant
biopsies and 11 of these remained positive after transplantation. Another 11 patients became positive
after the surgery (p = 0.05). CMV disease occurred in 17 recipients; 10 of these 17 (58.8%) patients were
positive for HHV-6 DNA in pre-transplant biopsies and they continued positive after transplantation
(p = 0.0128). Twenty-eight patients were transplanted due to hepatitis C; 12 of these patients had
recurrence of the virus, and HHV-6 was positive in nine of the 12 (75%) patients (p = 0.049).
Conclusions: Recipients with HHV-6 DNA in pre-transplant graft biopsies remained positive post
transplantation, showing a possible risk for post-transplant allograft loss because there was an
association between HHV-6 and recurrent HCV and CMV disease.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Herpesvirus reactivation is a common occurrence after liver
transplantation, and cytomegalovirus (CMV) and human herpes-
virus 6 (HHV-6) infections cause severe diseases in these
recipients.1 Seronegative recipients of liver allografts from CMV-
seropositive donors are at risk of CMV disease. Secondary infection
by reactivation or superinfection may also lead to CMV disease
during immunosuppression,2 and HHV-6 reactivates from latency
during the ﬁrst post-transplant months, often together with CMV
infection.3,4
These viruses are classiﬁed in the B-herpesvirus family.
Infection occurs in childhood and then subsequently results in* Corresponding author. Tel.: +55 19 3521 8582; fax: +55 19 3289 1577.
E-mail addresses: ilkaboin@yahoo.com, carolguardia@yahoo.com.br
(I.d.F.S.F. Boin).
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doi:10.1016/j.ijid.2011.10.008life-long latency, such that the seroprevalence rate in adults is over
90%.5,6 Therefore, in adult solid organ transplant recipients,
reactivation of endogenous latent viruses seems to occur very
frequently, with reported infection rates of 30–50%.7,8 Both viruses
can cause several human diseases either as a consequence of
reinfection or reactivation of latent infection.9,10 CMV is reacti-
vated during periods of stress and cytokine release, which happens
in liver transplant recipients, wherein the pharmacologic-induced
impairment of the immune response to ‘endogenously reactivated’
or ‘allograft-transmitted’ CMV leads to febrile and tissue invasive
diseases.11,12 HHV-6 reactivation and infections after liver
transplantation are asymptomatic, although the risk factors are
not completely deﬁned. Nonetheless, clinical syndromes have been
associated with HHV-6 infection after liver transplantation, and
these have been classiﬁed either as direct or indirect effects,13 so
HHV-6 may cause clinically relevant indirect effects such as CMV
disease and early ﬁbrosis caused by the recurrence of hepatitis C
virus (HCV).6,7,14ses. Published by Elsevier Ltd. All rights reserved.
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liver transplantation.15 The recurrence of the disease after
transplantation is universal and many factors have been associated
with it, including CMV infection.16 The interaction between
herpesviruses and HCV has been proposed to be clinically
important in HCV-infected liver transplant recipients,17 including
more severe forms of HCV recurrence. Patients with HCV infection
have been shown to be more susceptible to infections that are
associated with defects in cell-mediated immunity, such as CMV
and fungal infections.11,18–21
Our study analyzed the presence of CMV DNA and HHV-6 DNA
in liver biopsies from the donor patients collected at bench surgery
and from the post-transplanted period, and correlated these
viruses with the occurrence of CMV disease and HCV recurrence.
2. Patients and methods
During the period January 2005 to December 2007, a total of
41 liver transplant patients, transplanted at the Liver Transplant
Unit, Clinical Hospital of the State University in Campinas
(Unicamp), were enrolled in this study. This was an observa-
tional, analytic, longitudinal cohort and prospective study. The
following patients were excluded from the study: children and
cases of fulminant hepatitis, retransplantation, or death occur-
ring during the ﬁrst month after transplantation. The 41 patients
who were enrolled met the following inclusion criteria: (1)
survival in the post-transplantation period for >1 month; (2)
indication for at least one liver biopsy post transplantation; (3)
sufﬁcient liver biopsy samples for DNA virus analysis by nested
PCR method.
The ﬁrst liver biopsy was collected from the organ at the bench
before transplantation (pre-transplant graft biopsy). The other
liver biopsies (post-transplant graft biopsies) were collected
during the 6-month period after transplantation and when
clinically indicated (due to elevated liver enzyme levels). All
samples were formalin-ﬁxed and parafﬁn-embedded until the
moment of analysis. They were analyzed by nested PCR for CMV
DNA and HHV-6 DNA. Liver biopsies were also monitored for
recurrent HCV.
All patients included in this study had been given prophylaxis
for herpes simplex infection with 200 mg of acyclovir twice a day
for 60 days. The patients with CMV disease were treated
intravenously with ganciclovir 5 mg/kg twice a day for 2 weeks.
All recipients and donors had positivity for CMV IgG before
transplantation and there was no serology for HHV-6 before
transplantation.
All patients underwent standard immunosuppressive therapy
based on calcineurin inhibitors: cyclosporine A (CyA; 4–8 mg/kg)
and FK506 (0.1 mg/kg) and steroids until the 180th day after the
transplant, with tapering and withdrawal. The initial CyA blood
level was 200–400 ng/ml in the ﬁrst 3 months and then 150–250
ng/ml for a further month. The FK506 blood level used was 8–
12 ng/ml in the ﬁrst 3 months and 5–10 ng/ml for a further month.
2.1. Clinical deﬁnitions
Hepatitis C recurrence and disease severity were classiﬁed with
a METAVIR score.22 All HCV liver transplant patients had HCV RNA
detected in the serum by conventional molecular methods prior to
liver transplantation.23–25 We analyzed the presence of CMV DNA
and HHV-6 DNA in the same biopsies that were diagnosed with the
recurrence of HCV after transplantation.
CMV disease was deﬁned according to previously published
criteria9 and required the presence of clinical symptoms accom-
panied by the detection or isolation of CMV in blood by virological
tests and/or histological detection in a biopsy specimen.2.2. Molecular tissue testing
Viral DNA was extracted from the liver biopsies using the
Qiagen Tissue Kit (Biotecnologia Brasil, SP, Brazil) in accordance
with the manufacturer’s instructions, with some modiﬁcations
performed in our service, and ﬁnal elution volumes of 30 ml.
2.3. CMV and HHV-6 nested PCR ampliﬁcation
Five microliters of extracted DNA were used for the nested PCR
for CMV and HHV-6 using a mixture containing speciﬁc primers for
CMV (CMV primers; Invitrogen, Sa˜o Paulo, Brazil), by the technique
previously described, with some modiﬁcations,26,27 and speciﬁc
primers for HHV-6 (HHV-6 primers; Invitrogen, Sa˜o Paulo, Brazil),
by the technique previously described, with some modiﬁcations.28
The ampliﬁcations were carried out on a Peltier Thermal Cycler
(MJ Research, Waltham, MA, USA). The nested PCR product was
analyzed under UV light after electrophoresis in agarose gel (Gibco-
BRL Life Technology, Carlsbad, CA, USA) in Tris–ethylenediaminete-
traacetic acid buffer (TEB) stained with ethidium bromide.
All primer sequences and PCR products were analyzed using the
GenBank database before initiating the study. PCR with primers for
beta-globin gene ampliﬁcation was performed on the samples to
detect possible false-negative results, which were not included in
this study.29
2.4. Statistical analysis
The variables were compared with non-parametric tests
(Gamma correlation and Chi-square test or Fisher’s exact test).
For all tests, p < 0.05 was considered statistically signiﬁcant.
This study was approved by the Institutional Ethics Committee
of the Faculty of Medical Sciences, Unicamp (CEP number 030/
2006).
3. Results
Forty-one transplant recipients were studied (32 men and nine
women), with a median age of 48 (range 18–67) years. The main
indication for the transplant was HCV (16 patients); other
indications were HCV and alcohol in 12, cryptogenic cirrhosis in
two, Wilson’s disease in one, alcoholic liver disease in three,
autoimmune hepatitis in two, primary biliary cirrhosis in one,
primary sclerosing cholangitis in one, and hepatitis due to the
hepatitis B virus in three.
3.1. CMV DNA and HHV-6 DNA in liver biopsies
Four patients (9.8%) were positive for CMV DNA in pre-
transplant graft biopsies. After transplantation three of them
remained positive in the post-transplant graft biopsies. From the
37 negative (pre-transplant graft biopsies) only 11 became positive
(Table 1) in post-transplant graft biopsies (p = 0.06; Fisher’s exact
test; Table 2).
Fifteen patients (36.6%) were positive for HHV-6 DNA in pre-
transplant graft biopsies, and 11 of these patients remained positive
in post-transplant graft biopsies. Of the 26 negative patients, 11
became positive (Table 1) for this virus after the transplantation. The
patients who were positive for HHV-6 DNA in the pre-transplant
graft biopsy had a tendency (p = 0.05; Fisher’s exact test; Table 2) to
remain positive in the post-transplant graft biopsies.
3.2. Herpesvirus infection and CMV disease
CMV disease occurred in 17 of the 41 liver transplantation
patients (41.5%), and they were treated with ganciclovir. Two of
Table 1
CMV DNA and HHV-6 DNA monitoring in pre-transplant graft biopsies and post-transplant graft biopsies related with CMV disease and recurrence of HCV
Patient Pre-transplant biopsya
CMV DNA
Pre-transplant biopsya
HHV-6 DNA
Post-transplant biopsyb
CMV DNA
Post-transplant biopsyb
HHV-6 DNA
CMV diseasec HCV
recurrenced
METAVIR
(HCV-pos)
3e Negative Positive Negative Positive Positive Positive F1A2
6e Negative Positive Positive Positive Negative Positive F2A3
12e Negative Positive Negative Positive Positive Positive F3A2
17e Negative Positive Negative Positive Positive Positive F2A2
18e Negative Positive Positive Positive Positive Positive F1A1
20e Negative Negative Negative Positive Positive Positive F3A3
26e Negative Negative Positive Positive Negative Positive F2A2
31e Negative Negative Positive Positive Negative Positive F1A1
40e Negative Positive Negative Positive Negative Positive F1A3
11e Negative Negative Negative Negative Positive Positive F2A3
28e Negative Negative Negative Negative Negative Positive F1A2
1e Negative Positive Negative Negative Negative Positive F1A1
2e Positive Positive Positive Positive Negative Negative -
5e Negative Negative Negative Negative Negative Negative -
7e Negative Negative Positive Positive Negative Negative -
9e Negative Negative Positive Positive Positive Negative -
10e Negative Negative Negative Negative Negative Negative -
14e Negative Positive Positive Positive Positive Negative -
15e Negative Negative Negative Negative Negative Negative -
16e Negative Negative Negative Negative Negative Negative -
19e Positive Positive Positive Positive Negative Negative -
21e Negative Negative Negative Negative Negative Negative -
25e Negative Negative Negative Negative Negative Negative -
29e Negative Negative Negative Negative Negative Negative -
32e Negative Negative Negative Negative Negative Negative -
35e Negative Negative Positive Positive Positive Negative -
36e Negative Negative Negative Negative Negative Negative -
38e Positive Positive Negative Negative Positive Negative -
8 Negative Positive Positive Positive Positive Negative -
13 Negative Positive Positive Positive Positive Negative -
24 Positive Negative Positive Negative Positive Negative -
33 Negative Negative Negative Negative Positive Negative -
34 Negative Positive Negative Negative Positive Negative -
39 Negative Negative Negative Positive Positive Negative -
41 Negative Positive Negative Negative Positive Negative -
4 Negative Negative Negative Positive Negative Negative -
22 Negative Negative Negative Positive Negative Negative -
23 Negative Negative Negative Positive Negative Negative -
30 Negative Negative Positive Positive Negative Negative -
27 Negative Negative Negative Negative Negative Negative -
37 Negative Negative Negative Negative Negative Negative -
CMV, cytomegalovirus; HHV-6, human herpesvirus 6; HCV, hepatitis C virus.
a Pre-transplant graft biopsy: at the bench procedure.
b Post-transplant graft biopsy: after the transplantation, when clinically indicated according to the liver team.
c CMV disease: clinical disease treated with ganciclovir.
d HCV recurrence: recurrence of hepatitis C virus after transplantation.
e Patients were transplanted due to hepatitis C.
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and one remained positive in the post-transplant graft biopsy.
From the 15 negative patients, six became positive after
transplantation (Table 1). We found no signiﬁcant difference in
the presence of CMV DNA in pre-transplant graft biopsies and post-
transplant graft biopsies for the patients who had CMV disease
(Table 3).Table 2
CMV DNA and HHV-6 DNA monitoring observed in pre-transplant graft biopsies and p
CMV DNA (n = 41) 
Pre-transplanta Post-transplantb
4 Positive 3 Positive 
1 Negative 
37 Negative 11 Positive 
26 Negative 
Fisher’s exact test p = 0.06 
CMV, cytomegalovirus; HHV-6, human herpesvirus 6.
a Pre-transplant graft biopsy: at the bench procedure.
b Post-transplant graft biopsy: after the transplantation, when clinically indicated acTen of the 17 patients who had CMV disease were positive in
pre-transplant graft biopsies for HHV-6 DNA, of whom seven
continued positive after transplantation. From the seven negative
in pre-transplant graft biopsies, four became positive in post-
transplant graft biopsies (Table 1 and Table 3). This comparison
showed a higher CMV disease prevalence among patients who
were positive for HHV-6 DNA than among patients who wereost-transplant graft biopsies
HHV-6 DNA (n = 41)
Pre-transplanta Post-transplantb
15 Positive 11 Positive
4 Negative
26 Negative 11 Positive
15 Negative
Fisher’s exact test p = 0.05
cording to the liver team.
Table 3
Comparison of CMV DNA and HHV-6 DNA positivity observed among patients with CMV disease after liver transplantation (n = 17/41)
CMV DNA (n = 17/41) HHV-6 DNA (n = 17/41)
Pre-transplanta Post-transplantb Pre-transplanta Post-transplantb
2 Positive 1 Positive 10 Positive 7 Positive
1 Negative 3 Negative
Fisher’s exact test p = 1.0000 Chi-square, p = 0.0128c
15 Negative 6 Positive 7 Negative 4 Positive
9 Negative 3 Negative
Chi-square, p = 0.4243 Chi-square, p = 0.2325
CMV, cytomegalovirus; HHV-6, human herpesvirus 6.
a Pre-transplant graft biopsy: at the bench procedure.
b Post-transplant graft biopsy: after the transplantation, when clinically indicated according to the liver team.
c Statistically signiﬁcant.
Table 4
Comparison of CMV DNA and HHV-6 DNA post-transplanta positivity among
patients with recurrent hepatitis C virus
HCV hepatitis liver recipients (n = 28)
Recurrent HCV (n = 12) Without recurrent HCV (n = 16)
CMV DNA
Positive 4 6
Negative 8 10
Fisher’s exact test p = 1.000
HHV-6 DNA
Positive 9 6
Negative 3 10
Fisher’s exact test p = 0.049b
CMV, cytomegalovirus; HHV-6, human herpesvirus 6; HCV, hepatitis C virus.
a Post-transplant graft biopsy: after the transplantation, when clinically
indicated according to the liver team.
b Statistically signiﬁcant.
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(p = 0.013; Chi-square test).
Twenty-four recipients did not have CMV disease and just ﬁve
were positive in pre-transplant graft biopsies for HHV-6 DNA.
3.3. Herpesvirus infection and recurrent hepatitis C
In our study 28 (68.3%) of the patients were transplanted due to
hepatitis C, and 12 (42.9%) of them had recurrence of the virus after
the transplant. A METAVIR score was applied to all patients with
HCV recurrence (Table 1).
We observed that four of the 12 (33.3%) patients with
recurrence had CMV DNA positivity in post-transplant graft
biopsies; we did not verify any correlation between the presence
of CMV DNA in post-transplant graft biopsies and the same
biopsies with HCV recurrence (p = 1.00; Fisher’s exact test; Table
4).
When we analyzed the correlation between the presence of
HHV-6 DNA in post-transplant graft biopsies and HCV recurrence,
we found nine of the 12 (75%) recipients to be positive in post-
transplant graft biopsies, and six of the nine had already been
positive in pre-transplant graft biopsies (Table 1). After the
statistical analyses we observed that the nine patients who were
positive for the HHV-6 DNA developed more HCV recurrence
(p = 0.049; Fisher’s exact test; Table 4).
4. Discussion
Some previous studies have suggested that CMV and HHV-6
infections are frequent in liver transplant recipients in our Liver
Transplant Unit (Unicamp).8,30,31 CMV, HHV-6, and HHV-7
infections are common after liver transplantation, and the
interaction of these viruses can increase their pathogeniceffects.32,33 Overall, the incidence of HHV-6 infection after liver
transplantation reported in the literature varies from 14% to 82%.32
Thomasini et al. detected 65% positivity for CMV DNA in blood
samples from liver transplanted patients by nested PCR.33
In our study, the presence of CMV DNA was observed in 9.8%
and the presence of HHV-6 DNA in 36.6% of pre-transplant graft
biopsies. We could ﬁnd no published data to conﬁrm these data
and no similar data, but it is known that these viruses can have an
incidence over 80% (serologic status) in the human population.17,34
The same results were obtained by Costa in Brazil.35 This is an
important factor because the herpesviruses can establish a latent
infection for the lifetime of the host and reactivate later.36
A recent study carried out in patients who underwent liver
transplantation at the Hospital de Clinicas, State University of
Campinas (Unicamp) showed CMV positivity (IgG) in 94.7% of
patients before transplantation. They related the importance of
serological investigations and diagnostic examinations before the
transplantation procedure, seeking to minimize possible reactiva-
tion of the disease after the use of immunosuppressive drugs,
particularly in the ﬁrst 6 months after transplantation, or even to
avoid a primary infection.37
In our study, most biopsies remained positive after transplanta-
tion showing us that the presence of CMV DNA and HHV-6 DNA in
pre-transplant graft biopsies had a tendency to remain positive after
the transplantation. The literature on tissue viral load is mostly
limited to CMV and HHV-6, especially in relation to biopsies pre and
post transplantation. However, in a study by Sebekova´ et al., in
which herpesviruses were detected in the allograft biopsies by PCR,
the HHV-6 DNA was the most commonly found. A qualitative tissue
PCR may also detect latent or chromosomally integrated HHV-6
sequences, not necessarily an indicator of active infection, but
positive intragraft HHV-6 antigens represent protein synthesis
suggesting that HHV-6 may persist in the allograft in a manner
similar to its close relative CMV.4,38,39 This conﬁrms previous
studies, in which patients with pre-transplant HHV-6 evidence also
showed HHV-6 antigens in the post-transplant biopsies.40
Molecular assays are the most commonly used laboratory
methods to detect herpesvirus reactivation and replication after
transplantation. Both quantitative and qualitative methods have
been developed to detect CMV DNA and HHV-6 DNA in blood
samples, biopsy and tissue specimens. The polymerase chain
reaction allows for ampliﬁcation of regions of the genome to be
studied from small amounts of DNA and is therefore a method of
choice for use in tissues ﬁxed in formalin and embedded in
parafﬁn.41 Research in older tissue samples preserved in parafﬁn
requires the use of primers that generate products with fewer base
pairs.42
Seventeen (41.5%) of our 41 recipients developed the CMV
disease. Although it is estimated that 25% of all liver transplant
recipients will develop CMV disease32 because of the lack of a pre-
existing CMV-speciﬁc immunity, CMV-seronegative recipients of a
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the highest risk of CMV disease and its complications.43,44
However, all patients had CMV IgG positive serology in the pre-
transplant period and none had a serological status for HHV-6.
Ten of the 17 recipients who had CMV disease showed HHV-6
DNA in pre-transplant graft biopsies and they continued positive
after transplantation, although the CMV DNA in pre-transplant
graft biopsies did not have a signiﬁcant relationship with CMV
disease.
Fitzgerald et al. demonstrated that the CMV serologic status of
the donor and recipient are the most important factors in
determining the development of severe CMV disease and
consequently the downstream effect on the transplanted organ.45
There was a statistically signiﬁcant difference in the presence of
HHV-6 DNA in pre-transplant graft biopsies between recipients
who showed and did not show CMV disease after liver
transplantation (p < 0.0128). This indicates that a pre-transplant
HHV-6 infection may be a risk factor for CMV after transplantation.
This is because the indirect effects attributed to HHV-6 include an
exacerbation of CMV disease, an increased severity of HCV
recurrence, and an increased risk of other opportunistic infections,
allograft dysfunction, and acute cellular rejection. It is very
common to have a high prevalence of this virus in the population,
but its presence and replication in the tissue can be intensiﬁed
after transplantation and increase its replication.17,19,46–48
Most of our patients had an indication for liver transplant due to
liver cirrhosis caused by HCV. The recurrence of hepatitis C
occurred in 12 of the 28 (42.9%) recipients; nine of 12 (75%)
showed HHV-6 DNA in post-transplant graft biopsies and six of
these were positive in pre-transplant graft biopsies. Thirty-three
percent were positive for CMV DNA in post-transplant graft
biopsies.
The recurrence of HCV is nearly universal and leads to chronic
hepatitis in 20–40% of recipients after liver transplantation.49
Also, an interaction between herpesvirus and HCV has been
proposed to be clinically important in HCV-infected liver
transplant recipients.9,24,25
Our results demonstrated that the presence of HHV-6 DNA in
patients who developed HCV recurrence was signiﬁcant
(p = 0.049), differing from those patients who did not have
HHV-6 DNA in their post-transplant graft biopsies; this showed
that these viruses may facilitate HCV recurrence. Previous studies
have shown that CMV and HHV-6 have immunomodulatory
effects, and have suggested more rapid progression of HCV in liver
transplant recipients co-infected with this virus.9,24,25,50 Never-
theless, in our study the incidence of CMV DNA was not signiﬁcant
when compared to the HCV recurrence after liver transplantation,
and there was also no association with ﬁbrosis score (p = 0.4).
In another study involving 66 liver transplantation patients
with HCV infection, no correlation was observed between HHV-6,
CMV, and HCV viral loads, although more severe degrees of ﬁbrosis
and hepatitis were seen in patients with CMV disease and HHV-6
infection.17 Given our small recurrence group, it was perhaps not
possible to identify an association with the ﬁbrosis score.
We found that most of our patients with recurrence had HHV-6
DNA. This was also found in the study by Singh et al., which
reported that HCV-positive patients who developed HHV-6
viremia after liver transplantation had an earlier recurrence and
a higher ﬁbrosis score upon hepatitis C recurrence when compared
to patients without viremia.19 However, our study showed that
HHV-6 DNA was already present in pre-transplant graft biopsies.
Chronic HCV infection does not appear to cause herpesvirus
reactivation or replication, reinforcing the hypothesis of previous
studies that herpesvirus infections bring about HCV replication,
accelerating the progression of liver disease due to HCV.51
Although there is no deﬁnitive evidence that HHV-6 is involvedin direct clinical manifestations after liver transplantation,
associations with indirect effects previously attributed to it have
been demonstrated.52
In summary, most of the recipients with HHV-6 DNA in pre-
transplant graft biopsies remained positive after transplantation,
showing a possible risk for post-transplant allograft loss, because
there was an association between HHV-6 and recurrent HCV and
CMV disease. However, further studies are necessary to clarify
these data, especially HHV-6 infection in donor samples, which are
well known to have a negative impact on transplant outcome. This
issue is under investigation by our group.
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